144 related articles for article (PubMed ID: 9284204)
1. Neuroendocrine differentiation and prognosis in prostatic adenocarcinoma.
McWilliam LJ; Manson C; George NJ
Br J Urol; 1997 Aug; 80(2):287-90. PubMed ID: 9284204
[TBL] [Abstract][Full Text] [Related]
2. Neuroendocrine differentiation in metastatic prostatic adenocarcinoma.
Aprikian AG; Cordon-Cardo C; Fair WR; Zhang ZF; Bazinet M; Hamdy SM; Reuter VE
J Urol; 1994 Apr; 151(4):914-9. PubMed ID: 8126824
[TBL] [Abstract][Full Text] [Related]
3. Selected markers (chromogranin A, neuron-specific enolase, synaptophysin, protein gene product 9.5) in diagnosis and prognosis of neuroendocrine pulmonary tumours.
Kasprzak A; Zabel M; Biczysko W
Pol J Pathol; 2007; 58(1):23-33. PubMed ID: 17585539
[TBL] [Abstract][Full Text] [Related]
4. Tissue microarray analysis of neuroendocrine differentiation and its prognostic significance in breast cancer.
Makretsov N; Gilks CB; Coldman AJ; Hayes M; Huntsman D
Hum Pathol; 2003 Oct; 34(10):1001-8. PubMed ID: 14608533
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine serum tumour markers in hormone-resistant prostate cancer.
Hvamstad T; Jordal A; Hekmat N; Paus E; Fosså SD
Eur Urol; 2003 Aug; 44(2):215-21. PubMed ID: 12875941
[TBL] [Abstract][Full Text] [Related]
6. Secretagogin is a novel marker for neuroendocrine differentiation.
Birkenkamp-Demtröder K; Wagner L; Brandt Sørensen F; Bording Astrup L; Gartner W; Scherübl H; Heine B; Christiansen P; Ørntoft TF
Neuroendocrinology; 2005; 82(2):121-38. PubMed ID: 16449819
[TBL] [Abstract][Full Text] [Related]
7. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors.
Cussenot O; Villette JM; Cochand-Priollet B; Berthon P
Prostate Suppl; 1998; 8():43-51. PubMed ID: 9690663
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of neuroendocrine differentiation, proliferation activity and androgen receptor expression in prostate cancer.
Segawa N; Mori I; Utsunomiya H; Nakamura M; Nakamura Y; Shan L; Kakudo K; Katsuoka Y
Pathol Int; 2001 Jun; 51(6):452-9. PubMed ID: 11422807
[TBL] [Abstract][Full Text] [Related]
9. Neuroendocrine differentiation in prostatic carcinomas. A retrospective autopsy study.
Turbat-Herrera EA; Herrera GA; Gore I; Lott RL; Grizzle WE; Bonnin JM
Arch Pathol Lab Med; 1988 Nov; 112(11):1100-5. PubMed ID: 2460064
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine differentiation and prognosis in breast adenocarcinoma.
Miremadi A; Pinder SE; Lee AH; Bell JA; Paish EC; Wencyk P; Elston CW; Nicholson RI; Blamey RW; Robertson JF; Ellis IO
Histopathology; 2002 Mar; 40(3):215-22. PubMed ID: 11895486
[TBL] [Abstract][Full Text] [Related]
11. Augmented expression of chromogranin A and serotonin in peri-malignant benign prostate epithelium as compared to adenocarcinoma.
Sion-Vardy N; Tzikinovsky A; Bolotyn A; Segal S; Fishman D
Pathol Res Pract; 2004; 200(7-8):493-9. PubMed ID: 15462496
[TBL] [Abstract][Full Text] [Related]
12. Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma.
Cussenot O; Villette JM; Valeri A; Cariou G; Desgrandchamps F; Cortesse A; Meria P; Teillac P; Fiet J; Le Duc A
J Urol; 1996 Apr; 155(4):1340-3. PubMed ID: 8632569
[TBL] [Abstract][Full Text] [Related]
13. The expression of neuropeptides in hyperplastic and malignant prostate tissue and its possible clinical implications.
Yu DS; Hsieh DS; Chen HI; Chang SY
J Urol; 2001 Sep; 166(3):871-5. PubMed ID: 11490236
[TBL] [Abstract][Full Text] [Related]
14. Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer.
Ather MH; Abbas F; Faruqui N; Israr M; Pervez S
BMC Urol; 2008 Dec; 8():21. PubMed ID: 19115997
[TBL] [Abstract][Full Text] [Related]
15. [Role of neuroendocrine cells in prostate cancer progression].
Sciarra A; Innocenzi M; Ravaziol M; Minisola F; Alfarone A; Cattarino S; Panebianco V; Buonocore V; Gentile V; Di Silverio F
Urologia; 2011; 78(2):126-31. PubMed ID: 21574145
[TBL] [Abstract][Full Text] [Related]
16. Neuroendocrine differentiation is a relevant prognostic factor in stage III-IV colorectal cancer.
Grabowski P; Schindler I; Anagnostopoulos I; Foss HD; Riecken EO; Mansmann U; Stein H; Berger G; Buhr HJ; Scherübl H
Eur J Gastroenterol Hepatol; 2001 Apr; 13(4):405-11. PubMed ID: 11338071
[TBL] [Abstract][Full Text] [Related]
17. Expression of Insulinoma-Associated Protein 1 (INSM1) and Orthopedia Homeobox (OTP) in Tumors with Neuroendocrine Differentiation at Rare Sites.
Roy M; Buehler DG; Zhang R; Schwalbe ML; Baus RM; Salamat MS; Lloyd RV; Rosenbaum JN
Endocr Pathol; 2019 Mar; 30(1):35-42. PubMed ID: 30523500
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of histologic demonstration of chromogranin A and neuron specific enolase in pulmonary adenocarcinoma.
Skov BG; Sørensen JB; Hirsch FR; Larsson LI; Hansen HH
Ann Oncol; 1991 May; 2(5):355-60. PubMed ID: 1954180
[TBL] [Abstract][Full Text] [Related]
19. [Relation between neuroendocrine expression of prostatic carcinoma and prognosis].
Huang ZY; Meng FQ; Chen H
Zhonghua Yi Xue Za Zhi; 1994 Jan; 74(1):23-5, 62-3. PubMed ID: 8032980
[TBL] [Abstract][Full Text] [Related]
20. Primary carcinoid tumor of the prostate with concurrent adenocarcinoma: a case report.
Ghannoum JE; DeLellis RA; Shin SJ
Int J Surg Pathol; 2004 Apr; 12(2):167-70. PubMed ID: 15173926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
